Translating Engineered AAV Capsids Into Manufacturable Gene Therapies
By Jacob Smith, Head of Technical Development and CMC Strategy, Viralgen, Sabrina Triffault, Study Director, Preclinical and Clinical Testing, GenoSafe, Laurence Jeanson-Leh, Quality Control Manager, GenoSafe, Jacob Staudhammer, Senior Principal, Dark Horse Consulting Group, and Daniel Lourenco, Senior Consultant, Dark Horse Consulting Group
Access The White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of ECM Connection? Subscribe today.
Subscribe to ECM Connection
X
Subscribe to ECM Connection